Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has shared an update.
Avacta Group PLC has announced the sale of Coris Bioconcept SRL to 3B BlackBio Dx Ltd for £2.15 million, with additional potential earn-outs. This move marks the final step in Avacta’s transition to a pure-play therapeutics company, allowing it to focus on its pre|CISION® platform for oncology treatments. The sale is expected to extend the company’s cash runway into Q1 2026 and follows a previous divestment, reinforcing Avacta’s strategic shift towards its core therapeutics business.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc faces severe financial and operational challenges, reflected in its negative profitability and need for external financing. Despite strategic initiatives and promising clinical developments, the company’s financial instability poses significant risks. Technical indicators suggest potential pullback risks, reinforcing a cautious stance.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing highly potent cancer therapies using its proprietary pre|CISION® platform. This platform is designed to deliver targeted oncology treatments by concentrating potent payloads in tumor environments while minimizing impact on normal tissues. Avacta’s pipeline includes peptide drug conjugates and Affimer® drug conjugates, which offer advantages over traditional antibody drug conjugates.
Average Trading Volume: 2,165,670
Technical Sentiment Signal: Hold
Current Market Cap: £190.3M
For an in-depth examination of AVCT stock, go to TipRanks’ Overview page.